Leerink Partnrs Weighs in on Tourmaline Bio FY2029 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Research analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Tourmaline Bio in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($3.15) per share for the year. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($2.99) per share.

Tourmaline Bio (NASDAQ:TRML) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.06.

Other equities research analysts also recently issued reports about the stock. BMO Capital Markets assumed coverage on shares of Tourmaline Bio in a research note on Friday, December 6th. They set an “outperform” rating and a $50.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Guggenheim reissued a “buy” rating on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $49.00 price target on shares of Tourmaline Bio in a report on Wednesday, December 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Tourmaline Bio presently has a consensus rating of “Buy” and a consensus target price of $54.00.

Tourmaline Bio Price Performance

NASDAQ TRML opened at $14.28 on Friday. The business’s 50-day simple moving average is $20.01 and its 200-day simple moving average is $21.08. The firm has a market capitalization of $366.14 million, a P/E ratio of -5.06 and a beta of 2.32. Tourmaline Bio has a 1-year low of $12.12 and a 1-year high of $48.31.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TRML. Geode Capital Management LLC increased its stake in Tourmaline Bio by 6.4% during the third quarter. Geode Capital Management LLC now owns 482,078 shares of the company’s stock valued at $12,396,000 after purchasing an additional 29,005 shares during the last quarter. Wellington Management Group LLP raised its stake in Tourmaline Bio by 72.8% during the third quarter. Wellington Management Group LLP now owns 65,741 shares of the company’s stock worth $1,690,000 after acquiring an additional 27,707 shares during the period. State Street Corp lifted its holdings in Tourmaline Bio by 25.6% in the third quarter. State Street Corp now owns 411,980 shares of the company’s stock worth $10,592,000 after acquiring an additional 83,949 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Tourmaline Bio by 3.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 63,571 shares of the company’s stock valued at $1,634,000 after acquiring an additional 2,147 shares during the period. Finally, Barclays PLC grew its holdings in shares of Tourmaline Bio by 283.7% during the third quarter. Barclays PLC now owns 31,833 shares of the company’s stock valued at $819,000 after purchasing an additional 23,536 shares during the last quarter. Institutional investors own 91.89% of the company’s stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.